Latest / Stock Movers / Novo and Dayforce Jumps; Apple Headset
Transcript
- 0:00Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market,
- 0:13Speaker 1: harnessing the power of Bloomberg Data. Stockmovers is John Tucker's
- 0:18Speaker 1: a podcast. John decided to start out where I am John?
- 0:22Speaker 2: Did my body Mass Index this weekend? Yeah?
- 0:25Speaker 1: Came over did my BMI?
- 0:28Speaker 2: As they say, he said with Govy Novo nordis good
- 0:33Speaker 2: luck with that. Yeah, I mean I know a lot
- 0:36Speaker 2: of people who take it, but the side effects it
- 0:39Speaker 2: just you know, can vary from individual to individual. Now
- 0:42Speaker 2: there's apparently a new use for it. Novo shares advancing
- 0:46Speaker 2: after the drugmaker's blockbuster weight loss drug WEGV has now
- 0:51Speaker 2: received US approval to treat a serious form of liver disease.
- 0:57Speaker 2: The important part of this also is that they beat
- 0:59Speaker 2: one of their competitors, Eli Lilly to the US market,
- 1:03Speaker 2: So this particular approval gives Novo a big win in
- 1:06Speaker 2: the booming market for the GLP one drugs they of course,
- 1:10Speaker 2: have been popularized for weight loss. The drug makers started
- 1:14Speaker 2: the year as Europe's most valuable traded company, but it's
- 1:18Speaker 2: since lost about half of its value as it wrestles
- 1:22Speaker 2: with fierce competition in the obesity market. So the liver
- 1:26Speaker 2: clearance marks the second boost for Nova this month, after
- 1:29Speaker 2: disappointing data from Lily's obesity bill boosted investor hopes about
- 1:34Speaker 2: Novo's ability to Competegovie was clear for a disease known
- 1:39Speaker 2: as mash in adults with moderate to advance scar tissue
- 1:43Speaker 2: in the liver. A mash develops when fat builds up
- 1:46Speaker 2: in the liver, causing inflammation and potentially leading to more
- 1:50Speaker 2: serious conditions like cirrhosis and cancer. So Wgovie helps reverse
- 1:54Speaker 2: the damage to the liver, according to Novo nord Disk. Next,
- 1:59Speaker 2: let's go to a company called day Force, the ticker
- 2:03Speaker 2: symbol day so human resources management software provider. It is
- 2:08Speaker 2: the target of Tomo Bravo, the buyout firm planning to
- 2:12Speaker 2: take the Minneapolis based company private. This is a deal
- 2:16Speaker 2: that could be announced as soon as the coming weeks.
- 2:19Speaker 2: Day four shares they have fallen about the sixty percent
- 2:23Speaker 2: from their twenty twenty one peak, while the company increased
- 2:26Speaker 2: revenue more than seventy percent between twenty twenty one and
- 2:30Speaker 2: twenty twenty four and became more profitable again. This is
- 2:33Speaker 2: the enterprise software market. They make human resources software. This
- 2:39Speaker 2: market has had difficulties maintaining momentum after a run up
- 2:44Speaker 2: during the COVID nineteen lockdowns, and let's wrap up with
- 2:49Speaker 2: this one. We constantly asked the question Apple, where's its
- 2:53Speaker 2: mojo going? An interesting take from Mark German. He focuses
- 2:58Speaker 2: on Apple's Vision Pro headset. It isn't selling well for
- 3:02Speaker 2: a couple of reasons. First of all, it's thirty five
- 3:04Speaker 2: hundred dollars price sag, and then there's the lack of
- 3:07Speaker 2: sufficiently compelling features. There are other issues like a limited
- 3:11Speaker 2: array of custom applications and the device's weight and cumbersome
- 3:16Speaker 2: setup process. By all accounts, the device remains an extremely
- 3:21Speaker 2: niche product. Moreover, the headset doesn't feel like a priority
- 3:25Speaker 2: for Apple. On the the last earnings call, for instance,
- 3:28Speaker 2: Tim Cook almost seems surprised when a Wallstreet analyst quiz
- 3:31Speaker 2: him about the device and also the company's strategy. So
- 3:36Speaker 2: there you go. Mark Dermott strikes again on it.
- 3:39Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 3:43Speaker 1: us throughout the day for the latest roundup of companies
- 3:46Speaker 1: making news on Wall Street and for the latest market
- 3:49Speaker 1: moving headlines. Listen to Bloomberg Radio Live. Catch us on YouTube,
- 3:53Speaker 1: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:57Speaker 1: the Bloomberg Business appe